Results 171 to 180 of about 22,163,553 (318)

Novel attributes of HIV-1 elite controllers: redefining persistent HIV-1 remission. [PDF]

Curr Opin HIV AIDS
Ruiz-Mateos E.
europepmc   +1 more source

HIV/AIDS and STD Semiannual Report Incident, Prevalent, and Cumulative AIDS Cases in Kansas as of ... by Date of Report HIV/AIDS in Kansas Biannual Report ... HIV/AIDS in Kansas Annual Report ...

, 2009
Contains Incident, Prevalent, and Cumulative AIDS Cases in Kansas as of ... by Date of Report "HIV/AIDS and STD Semiannual Report is a publication of the Kansas Department of Health and Environment with funding assistance from the Centers for Disease ...
HIV/AIDS Surveillance Program
core  

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Correlation between IL-18 secretion by peripheral blood mononuclear cells and NK cells activation after SARS-CoV-2 booster vaccination in HIV-1-infected individuals

Infectious Diseases & Immunity
Xiuwen Wang, Xiaodong Yang, Xin Zhang, Wei Xia, Tong Zhang, Hao Wu, Bin Su, Haijuan Wang   +7 more
doaj   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Mechanisms of APOBEC3 Packaging into HIV-1. [PDF]

Viruses
Nzivo M, Gertzen CGW, Luedde T, Gohlke H, Münk C.   +4 more
europepmc   +1 more source

Genetic and immunological characterization of new subtype G envelope expressing HIV-1 pseudoviruses

, 2014
Includes bibliographical references.One of the greatest challenges for the development of an effective HIV-1 vaccine is the high genetic diversity of this pathogen and the complex escape mechanisms employed by the envelope gp120 and gp41 glycoprotein ...
Essomba, Rene Ghislain
core  

Inflammation‐driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients

British Journal of Clinical Pharmacology, EarlyView.
Aims Voriconazole is commonly used to prevent fungal infections after haematopoietic stem cell transplantation (HSCT). Although its metabolism is influenced by CYP2C19 genetics and inflammation, their combined effect is rarely considered in clinical practice, and integrated analyses remain limited.
Sylvia D. Klomp, Martijn L. Manson, Henk‐Jan Guchelaar, Stefan Böhringer, Esther H. M. van Egmond, Peter A. von dem Borne, Jesse J. Swen   +6 more
wiley   +1 more source

HIV-1 Non Group-M Phenotypic Susceptibility to Ibalizumab. [PDF]

J Med Virol
Poisson L, Hingrat QL, Lermechain F, Tombette F, Jullien H, Plantier JC, Alessandri-Gradt E.   +6 more
europepmc   +1 more source

Antibody-dependent enhancement of HIV-1 infection.

, 2007
Antibody-dependent enhancement (ADE) is the process by which virus-specific antibodies enhance entry or replication of a virus, leading to increased infection and the potential to exacerbate disease progression or severity. In terms of HIV infection, ADE
Willey, S., Willey, Suzanne
core